The healthcare and pharmaceutical industries are essential for global well-being, and their demand continues to grow with advancements in medicine and increasing healthcare needs. The Tata India Pharma & Healthcare Fund is designed to invest in companies within these industries, giving investors a way to participate in this growth.
What is the Tata India Pharma & Healthcare Fund?
This fund is a mutual fund that focuses on companies in the healthcare and pharmaceutical sectors. It invests in areas like:
- Medicine Manufacturing: Companies producing branded generic drugs for both domestic and export markets.
- APIs (Active Pharmaceutical Ingredients): These are the key components in medicines.
- Contract Research and Manufacturing (CRAMS): Firms that assist in drug development and production.
- Healthcare Services: Hospitals, diagnostics, and other related services.
The fund tracks the performance of the Nifty Pharma TRI index, aiming to align with trends in the healthcare and pharma industries.
Key Features of the Fund
- Diversification across Pharma and Healthcare Sectors:
The fund spreads its investments across big companies (large-cap), mid-sized companies (mid-cap), and smaller, fast-growing firms (small-cap) operating in different pharma & healthcare sector. - Sector-Specific Focus:
The fund targets sectors like medicine exports, healthcare services, and pharmaceutical research.
Why Consider Investing in Healthcare and Pharma?
- India’s Strength in Pharmaceuticals:
India is one of the world’s largest producers of generic drugs. Initiatives like the Production-Linked Incentive (PLI) scheme could further boost this industry. (Source: Business Standard) - Stability During Economic Downturns:
The healthcare sector often performs steadily even during tough economic times because people continue to need medical care and medicines. - Potential for Long-Term Growth:
Specialized areas like APIs, pharmaceutical research, and diagnostics are growing, offering opportunities for wealth creation over time.
Things to Keep in Mind Before Investing
- Sector-Specific Risks: This fund focuses solely on healthcare and pharma, so it can be affected by changes in regulations or market trends specific to this sector.
- Performance Variations: The fund's returns may differ from its benchmark due to operational costs.
- Long-Term Investment: This fund is better suited for investors who are willing to stay invested for several years to ride out market cycles.
The Tata India Pharma & Healthcare Fund is a way to invest in India’s growing healthcare and pharma sectors. It could be an option for those looking for focused exposure to this industry and its potential growth.
If you're looking to align your investments with the rising demand for healthcare services and pharmaceuticals, this fund might be worth considering as part of your portfolio
Scheme Details
- Scheme Name: Tata India Pharma & Healthcare Fund
- Scheme Category: Equity Scheme-Sectoral
- Scheme Type: An open-ended equity scheme investing in Pharma and Healthcare Services Sector.
- Fund Managers: Meeta Shetty & Rajat Srivastav
- Min. Investment Amount:
- Minimum amount for Lumpsum: Rs 5,000/- and in multiple of Re.1/- thereafter
- Minimum amount for SIP: Rs 100 and in multiples of Re 1/- thereafter
- Load Structure:
- Entry Load: Not Applicable
- Exit Load: 0.25% of NAV of redeemed/switched out before 30 days from the date of allotment. Applicable tax on exit load, if any, shall be paid out of the exit load proceeds and exit load net of tax, if any, shall be credited to the scheme.
This product is suitable for investors who are seeking*:
Scheme Risk-O-Meter | Benchmark Risk-O-Meter | |
| ![]() | ![]() |
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them. | ||
It may be noted that risk-o-meter specified above is based on internal assessment. The same shall be updated as per provision no. 17.4.1.i of SEBI Master Circular on Mutual Fund dated 27.06.2024, on Product labelling in mutual fund schemes on ongoing basis. |
*Mutual Fund investments are subject to market risks, read all scheme related documents carefully.